Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The current status of chemoprevention in FAP.

Literature DB >> 16998675

The current status of chemoprevention in FAP.

M H Wallace¹, P M Lynch.

Abstract

Mesh：

Substances：
Antineoplastic Agents

Year: 2006 PMID： 16998675 DOI： 10.1007/s10689-005-5676-0

Source DB: PubMed Journal: Fam Cancer ISSN： 1389-9600 Impact factor: 2.375

× No keyword cloud information.

28 in total

Review 1. Metabolic epidemiology of dietary factors in large bowel cancer.

Authors: M J Hill
Journal: Cancer Res Date: 1975-11 Impact factor: 12.701

2. Effect of sulindac on small polyps in familial adenomatous polyposis.

Authors: H S Debinski; J Trojan; K P Nugent; A D Spigelman; R K Phillips
Journal: Lancet Date: 1995-04-01 Impact factor: 79.321

3. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis.

Authors: T Kawamori; C V Rao; K Seibert; B S Reddy
Journal: Cancer Res Date: 1998-02-01 Impact factor: 12.701

4. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis.

Authors: R K S Phillips; M H Wallace; P M Lynch; E Hawk; G B Gordon; B P Saunders; N Wakabayashi; Y Shen; S Zimmerman; L Godio; M Rodrigues-Bigas; L-K Su; J Sherman; G Kelloff; B Levin; G Steinbach
Journal: Gut Date: 2002-06 Impact factor: 23.059

5. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse.

Authors: S H Erdman; N A Ignatenko; M B Powell; K A Blohm-Mangone; H Holubec; J M Guillén-Rodriguez; E W Gerner
Journal: Carcinogenesis Date: 1999-09 Impact factor: 4.944

6. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.

Authors: Marcia Cruz-Correa; Linda M Hylind; Katherine E Romans; Susan V Booker; Francis M Giardiello
Journal: Gastroenterology Date: 2002-03 Impact factor: 22.682

7. Sulindac for polyposis of the colon.

Authors: W R Waddell; R W Loughry
Journal: J Surg Oncol Date: 1983-09 Impact factor: 3.454

8. Rofecoxib reduces polyp recurrence in familial polyposis.

Authors: A Hallak; L Alon-Baron; R Shamir; M Moshkowitz; B Bulvik; E Brazowski; Z Halpern; N Arber
Journal: Dig Dis Sci Date: 2003-10 Impact factor: 3.199

9. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.

Authors: Tetsuro Higuchi; Takeo Iwama; Keigo Yoshinaga; Masahiro Toyooka; Makoto M Taketo; Kenichi Sugihara
Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531

3 in total